Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

被引：0
|
作者：
Richardson, Paul [1 ]
Sandhu, Irwindeep [2 ]
Oriol, Albert [3 ,4 ]
Raab, Marc S. [5 ]
White, Darrell [6 ,7 ]
LeBlanc, Richard [8 ]
Perrot, Aurore [9 ]
Ocio, Enrique [10 ]
Raje, Noopur [11 ]
Hansen, Charlotte Toftmann [12 ]
Zhou, Zehua [13 ]
Civardi, Tiziana [14 ]
Ghiddi, Alessandro [14 ]
Katz, Jessica [13 ]
Peluso, Teresa [14 ]
Dimopoulos, Meletios A. [15 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Alberta, Edmonton, AB, Canada
[3] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol, Badalona, Spain
[4] Hosp Badalona Germans Trias & Pujol, Josep Carreras Inst, Badalona, Spain
[5] Univ Klinikum Heidelberg, Heidelberg, Germany
[6] Dalhousie Univ, Halifax, NS, Canada
[7] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[8] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada
[9] Inst Univ Canc Toulouse Oncopole, Toulouse, France
[10] Hosp Univ Marques de Valdecilla IDIVAL, Santander, Spain
[11] Massachusetts Gen Canc Ctr, Boston, MA USA
[12] Odense Univ Hosp, Odense, Denmark
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Celgene Int Sarl, Boudry, Switzerland
[15] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Hematol & Med Oncol, Athens, Greece
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OAB-053
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 50 条
  • [21] PANOBINOSTATPK/PD IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITHRELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
    Mu, S.
    Tajima, T.
    Corrado, C.
    Sunami, K.
    Suzuki, K.
    Hino, M.
    Kuroda, Y.
    Shibayama, H.
    Lin, R.
    Waldron, E.
    Binlich, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S49 - S49
  • [22] A randomized phase II study of bortezomib (Btz)/dexamethasone (dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Jakubowiak, Andrzej J.
    Offidani, Massimo
    Pegourie, Brigitte
    De La Rubia, Javier
    Garderet, Laurent
    Laribi, Kamel
    Bosi, Alberto
    Marasca, Roberto
    Laubach, Jacob
    Mohrbacher, Ann
    Carella, Angelo Michele
    Singhal, Anil K.
    Tsao, Claire
    Lynch, Mark John
    Bleickardt, Eric W.
    Jou, Ying-Ming
    Palumbo, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Melflufen and dexamethasone (dex) plus bortezomib (BTZ) or daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) (OP-104)
    Pour, Ludek
    Efebera, Yvonne
    Granell, Miquel
    Hajek, Roman
    Oriol, Albert
    Delaunay, Jacques
    Le Du, Katell
    Eveillard, Jean-Richard
    Karlin, Lionel
    Maisnar, Vladimir
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Moreb, Jan
    Ribrag, Vincent
    Richardson, Paul G.
    Straub, Jan
    Byrne, Catriona
    Jacques, Christian
    Zubair, Hanan
    Ocio, Enrique
    CANCER RESEARCH, 2019, 79 (13)
  • [24] Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM)
    Atrash, Shebli
    Tullos, Amanda
    Panozzo, Susan
    Waheed, Sarah
    Van Rhee, Frits
    Restrepo, Alejandro
    Muzaffar, Jameel
    Bakhous, Aziz
    Grazziutti, Monica
    Shahid, Zainab
    Apewokin, Senu
    Abdallah, Al-Ola A.
    Barlogie, Bart
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).
    Berdeja, Jesus G.
    Gregory, Tara K.
    Matous, Jeffrey
    Hart, Lowell L.
    Owera, Rami
    Mace, Joseph Ronald
    Essell, James H.
    Flinn, Ian
    Faber, Edward Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Impact of renal impairment (RI) on pharmacokinetics (PK) and clinical outcomes with mezigdomide plus dexamethasone (DEX) in relapsed/refractory multiple myeloma (RRMM)
    Trudel, Suzanne
    Bahlis, Nizar J.
    Popat, Rakesh
    Mateos, Maria-Victoria
    Vangsted, Annette J.
    Ramasamy, Karthik
    Martinez-Lopez, Joaquin
    Quach, Hang
    Orlowski, Robert Z.
    Burnett, Joseph
    Gaudy, Allison
    Chen, Wencong
    Gong, Jing
    Hadala, Joseph T.
    Donahue, Cynthia
    Koo, Phillip
    Zhu, Yue
    Katz, Jessica
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).
    Moreau, P.
    Palumbo, A. P.
    Stewart, A. K.
    Rajkumar, V.
    Jakubowiak, A. J.
    Halka, K.
    Goranov, S.
    Bumbea, H.
    Pendergrass, K. B.
    Lupu, A.
    Dimopoulos, A.
    Rocafiguera, A. O.
    Gandhi, J. G.
    Mihaylov, G.
    Masszi, T.
    Matous, J.
    Fonseca, G.
    Bryce, R.
    Siegel, D. S. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [28] Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)
    Anderson, K. C.
    Jagannath, S.
    Jakubowiak, A.
    Lonial, S.
    Raje, N.
    Schlossman, R.
    Munshi, N.
    Knight, R.
    Esseltine, D.
    Richardson, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] A Phase 1 Study Of ARRY-520 With Bortezomib (BTZ) and Dexamethasone (dex) In Relapsed Or Refractory Multiple Myeloma (RRMM)
    Chari, Ajai
    Htut, Myo
    Zonder, Jeffrey
    Fay, Joseph W.
    Jakubowiak, Andrzej J.
    Harrison, Beverly
    Lau, Kenneth
    Hilder, Brandi
    Ptaszynski, Ann
    Rush, Selena A.
    Kaufman, Jonathan L.
    Burt, Steven Michael
    BLOOD, 2013, 122 (21)
  • [30] Daratumumab (Dara) and hyperfractionated cyclophosphamide (HyperCy)/dexamethasone (Dex) with and without carfilzomib (Car) for the treatment of relapsed/refractory multiple myeloma (RRMM).
    Shank, Brandon R.
    Primeaux, Brian
    Horowitz, Sandra B.
    Yeung, Erin K.
    Lee, Irene Y.
    Kaufman, Gregory Peter
    Lee, Hans Chulhee
    Manasanch, Elisabet Esteve
    Patel, Krina K.
    Orlowski, Robert Z.
    Weber, Donna M.
    Thomas, Sheeba K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345